International: +1-347-960-6455
Hemochromatosis Therapeutics

Hemochromatosis Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019

Report Code: PP10231 Report Type: Indication Pipeline Reports Pages: 200+ Available format: 
Therapeutic Area(s): Hematology
Select License Type


Hemochromatosis, also known as iron overload, is characterized by iron accumulation in human body. Some of the major symptoms of hemochromatosis/iron overload include weight loss, joint pain, erectile dysfunction in men, and irregular menstrual cycle in women. Hemochromatosis is mainly categorized into two types: primary hemochromatosis (genetic) and secondary hemochromatosis (caused by some other medical condition).

Hemochromatosis can lead to serious conditions such as liver damage, diabetes, arthritis, reproductive complications, and cardiovascular diseases, if the disease is not diagnosed or treated at an early stage. It is primarily diagnosed by blood test, and also thorough physical examination. To confirm the diagnosis, additional liver function test (LFT), magnetic resonance imaging (MRI), and liver biopsy are done.

Hemochromatosis Therapeutics

Exjade by Novartis International AG, and Ferriprox by ApoPharma Inc. are the key U.S. Food and Drug Administration (USFDA) approved therapies available in the market for the treatment of hemochromatosis.

In addition, positive clinical trial results and strategic decisions of companies to collaborate with other companies are also facilitating drug development in hemochromatosis pipeline. Additionally, the issuance of patents helps in achieving different milestones in the form of grants and designations from regulatory bodies and institutes, including the U.S. USFDA, the European Medicines Agency (EMA), and the National Institutes of Health (NIH), among others.

Pipeline Analysis

As of March 2019, the hemochromatosis therapeutics pipeline comprises 10+ therapeutic candidates in different stages of development.

Epidemiology Analysis

The report provides epidemiology forecast of hemochromatosis for seven major markets, such as the U.S., Japan, and EU5 countries (the U.K., Germany, France, Italy, and Spain). It covers prevalent population and treated patient population for the period 2016–2028.

Competitive Landscape

Some of the key players involved in the development of hemochromatosis therapeutics, include Novartis International AG, ApoPharma Inc., La Jolla Pharmaceutical Company, DisperSol Technologies, Silence Therapeutics plc, and Vifor Pharma Management Ltd.

Report Insights

Some highlights of the report “Hemochromatosis Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019”, include:

  • Detailed pipeline analysis of therapeutic candidates, which are being developed for the treatment of hemochromatosis, estimates and analyzes the emerging therapies and their progress status in different phases of development
  • Comprehensive insights into pipeline phase products, with special focus on strategic development activities, inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, patents, and upcoming conferences
  • Competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to hemochromatosis
  • Epidemiology forecast of hemochromatosis for seven major markets (referred to as 7MM in the report), which include the U.S., Japan, and EU5 countries
  • Analysis of marketed products for the treatment of hemochromatosis
  • Detailed regulatory framework for drug approval in the U.S., Europe, and Japan
  • Key winning strategies of companies involved in the hemochromatosis therapeutics development, followed by Pharma Proff’s views